Thymosin Alpha-1thymalfasin — the thymic immune-balancing peptide
Thymosin alpha-1 is a small immune-signaling peptide your body naturally makes — a fragment released from the thymus that helps coordinate T-cells, dendritic cells, and antiviral defenses. As the synthetic drug thymalfasin (Zadaxin) it's an approved medicine in 35+ countries for chronic hepatitis. Its strongest evidence is for specific medical conditions — not general "immune boosting" or anti-aging. In the U.S. it is not FDA-approved, and the FDA has flagged safety concerns about compounded versions.
A 28-amino-acid, N-acetylated thymic peptide that acts as an immunomodulator — recalibrating rather than simply stimulating immunity — through TLR2/TLR9 signaling on dendritic and myeloid cells. The best-developed human evidence is chronic hepatitis B/C (1.6 mg SC twice weekly). Thymalfasin is approved in many countries; in the U.S. it remains investigational, and recent high-quality data have tempered some claims — the large 2025 sepsis RCT was negative and COVID-19 data are conflicting.
Tα1 (thymalfasin; CAS 62304-98-7; C₁₂₉H₂₁₅N₃₃O₅₅, MW ≈ 3108 Da; PubChem CID 16130571; DrugBank DB04900) — sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, an N-acetylated fragment of the 109-residue precursor prothymosin alpha, first isolated from calf thymus by Goldstein's lab (1977). Heavily acidic (Asp/Glu-rich). It primes dendritic cells via TLR9/MyD88/IRF7 and links TLR9 signaling to IDO-dependent tolerance — a bidirectional immune-balancing profile.
A real drug abroad — investigational and indication-specific here.
Thymosin alpha-1 has a far stronger human evidence base than most "research peptides": decades of RCTs, meta-analyses, and approval as thymalfasin in 35+ countries. But that strength is indication-specific. The hepatitis data are historically meaningful yet partly superseded by modern antivirals; the sepsis story was reshaped by a large negative 2025 trial; COVID-19 data conflict. And in the U.S. it isn't approved — the FDA has flagged compounded Tα1 for immunogenicity and impurity risk. Read the evidence by condition, not as a blanket "immune optimizer."
🦠
Primary use case
Viral hepatitis
Best-developed evidence is immune modulation in chronic viral hepatitis (HBV), 1.6 mg SC twice weekly. Grade B.
🔀
Mechanism headline
Immune-balancing
Modulates immunity via dendritic-cell activation, TLR2/TLR9 signaling, and Th1 support — recalibration, not pure stimulation. Grade C/P.
📊
Strongest evidence
Human RCTs
Human RCTs and meta-analyses exist for HBV, HCV adjunct, sepsis, and COVID — but results vary sharply by indication. Grade A/B.
💉
Typical dose
1.6 mg 2×/wk
Most-cited outpatient regimen: 1.6 mg SC twice weekly for ~24–26 weeks in chronic hepatitis trials. Grade B.
📉
Evidence update
Sepsis: negative
The large 2025 TESTS phase 3 RCT found no clear 28-day mortality benefit in sepsis (23.4% vs 24.1%). Grade A.
💢
Key risk
Mild / immune
Mostly injection-site irritation; theoretical immune-activation risk in autoimmune disease and transplant settings. Grade D.
🏛️
US regulatory
Flagged
Not FDA-approved; FDA placed Tα1 in compounding Category 2 over immunogenicity/impurity concerns. Grade D.
⏱️
Pharmacokinetics
~2 h t½
Rapid SC absorption, peak ~2 h, return toward baseline within 24 h; immune effects build over weeks. Grade B.
02 · Mechanism of action
How Tα1 tunes the immune system.
Thymosin alpha-1 is best understood as an immune "signal tuner" rather than a simple stimulant. It engages Toll-like receptors (TLR2 and TLR9) on dendritic and myeloid cells, priming antigen presentation and pushing Th1-type antiviral responses — while simultaneously activating tolerance pathways (IDO) that keep the response balanced. This bidirectional profile is why it's called an immunomodulator. The receptor-and-cell biology is well-supported (Grade P/C); whether it changes clinical outcomes depends heavily on the disease context.
Tα1 helps antigen-presenting cells "show" immune targets more effectively.
Clinical significance: In human monocyte-derived dendritic-cell models, Tα1 enhances differentiation, activation markers, and antigen-presentation capacity. It modulates DC differentiation and functional maturation from human CD14+ monocytes.
Molecular detail: Reported effects include increased DC maturation, improved antigen-presenting function, and enhanced downstream T-cell activation — strongest in in-vitro and translational immune-cell studies. This DC-priming step seeds the adaptive response Tα1 is meant to support.
Clinical significance: Tα1 primes dendritic cells for antimicrobial Th1 resistance through TLR9 signaling — the proposed basis for its antiviral immune effects in hepatitis and other infections.
Molecular detail: Mechanistic work describes activation through TLR9 → MyD88 → IRF7, supporting type-I interferon and IL-12 pathways. These pathways are well-characterized preclinically, but pathway activation is not by itself a guarantee of clinical efficacy.
Grade C/P
🎛️
3 · TLR2 / TLR9 immune-sensing modulation
Tα1 acts like an immune "signal tuner," not a blunt stimulant.
Clinical significance: Reviews describe Tα1 functioning through TLR2 and TLR9 in myeloid and dendritic cells — dual receptor engagement that distinguishes it from single-pathway immune agents.
Molecular detail: TLR engagement drives NF-κB/IRF-dependent cytokine signaling, costimulatory activation, and antigen-presentation effects. The dual TLR2/TLR9 profile underlies both the stimulatory and the balancing arms of its action.
Grade B/C
🛡️
4 · Th1 cytokine & T-cell support
Tα1 is mainly positioned as a T-cell immune-support peptide.
Clinical significance: It stimulates T-cell differentiation/function and enhances Th1-type responses relevant to chronic viral infections. Clinical reviews describe enhanced IL-2, IFN-γ, and T-cell maturation.
Molecular detail: Th1 skewing supports cell-mediated antiviral immunity. Direct clinical biomarkers vary across trials — the cytokine effects are real in immunology assays but inconsistently translate to measurable clinical endpoints.
Grade C/P
🎯
5 · NK-cell / cytotoxic immune modulation
Tα1 may help immune surveillance cells respond more effectively.
Clinical significance: Viral-infection reviews describe effects on T- and NK-cell maturation and activation — relevant to both infection and oncology-adjunct rationales.
Molecular detail: Proposed downstream effects include increased cytotoxic-lymphocyte responsiveness and improved immune surveillance. Repeatedly discussed across reviews, but indication-specific clinical proof is mixed.
Grade P/C
⚖️
6 · IDO / immune-tolerance balancing
Tα1 can also help prevent overactive immune signaling in some contexts.
Clinical significance: Tα1/TLR9 signaling activates dendritic-cell tryptophan catabolism via IDO, establishing a regulatory environment — the tolerance arm that makes Tα1 "balancing," not just stimulating.
Molecular detail: TLR9-dependent IDO induction can drive regulatory T-cell and anti-inflammatory effects. This explains the bidirectional immunomodulatory framing; the validating clinical monitoring markers for it are not established.
Real clinical regimens — but US-investigational, FDA-flagged.
Unlike most atlas peptides, Tα1 has decades of defined clinical dosing — the classic 1.6 mg subcutaneous twice-weekly hepatitis regimen and short-course inpatient protocols. Those are real, literature-derived numbers, not guesses. But they are not U.S. prescribing guidance: Tα1 is not FDA-approved here, the FDA has placed it in compounding Category 2 over immunogenicity and impurity concerns, and only the subcutaneous route has substantial human precedent. The calculator handles mg reconstitution arithmetic. None of this is medical advice.
US: not FDA-approved · compounding safety-flagged
FDA placed thymosin alpha-1 in compounding Category 2: as a 28-aa SC peptide it may pose significant immunogenicity risk (potentially amplified by aggregation) plus peptide-impurity and API-characterization concerns; FDA materials proposed not including Tα1 free base/acetate on the 503A bulks list. Hepatitis, sepsis, and infection care belong with a clinician and standard-of-care therapy — not self-sourced peptide.
Pharmacokinetics
Human reviews describe rapid SC absorption, peak serum concentration within ~2 hours, return toward baseline within 24 hours, and a serum half-life of ~2 hours. There is no accumulation between twice-weekly doses; the immune-cell effects build over ~4–8 weeks of repeated dosing rather than from any single injection.
No routine escalation; classic trials used fixed dosing. Some studies compared 0.8 mg vs 1.6 mg.
Cycle length
24–26 weeks in HBV trials; HCV adjunct protocols sometimes extended to 48 weeks with interferon/ribavirin background.
Reconstitution
e.g. 5 mg vial + 2.5 mL BAC → 2 mg/mL; 1.6 mg = 0.8 mL = 80 U on a U-100 syringe.
Monitoring
ALT/AST, bilirubin, HBV DNA / HCV RNA, HBeAg where applicable, CBC, injection sites.
Not a U.S.-approved HBV/HCV treatment; modern antivirals (PEG-IFN, direct-acting antivirals) are standard of care. Do not replace antiviral therapy. Grade B (historical) · D (non-approved US use).
Dose bands · literature
Global dose-band table (literature-derived, not prescribing)
Band
Dose
≈ mg/kg @ 70 kg
Basis
Low
0.8 mg / injection
0.011
Dose-comparison hepatitis studies
Standard
1.6 mg, 2×/week
0.023
Most-cited clinical dose
High / acute
1.6 mg daily–q12h × 5–7 d
0.023–0.046/day
Sepsis/COVID inpatient designs
Very high / nonstandard
>1.6 mg/day short-course
Variable
Review-level range; not validated outpatient
Weight-band · exposure only
Fixed 1.6 mg → mg/kg (comparison only)
Body weight
Fixed dose
≈ mg/kg
55 kg
1.6 mg
0.029
65 kg
1.6 mg
0.025
75 kg
1.6 mg
0.021
85 kg
1.6 mg
0.019
95 kg
1.6 mg
0.017
105 kg
1.6 mg
0.015
Most protocols use fixed dosing, not weight-based titration. This table is for exposure comparison only.
The large 2025 RCT challenges earlier smaller positive meta-analyses. Not suitable for any consumer self-modeling. Grade A for trial existence; mixed/negative efficacy; D for extrapolation.
1.6 mg SC daily for ~1 week as an adjunct to standard care in at least one COVID-19 protocol (1.6 mg in 1 mL diluent).
Setting
Hospitalized adults, adjunct to standard care; not an outpatient or preventive protocol.
Evidence
A 9-study meta-analysis (5352 patients) found no statistically significant mortality effect, while another analysis suggested possible benefit in moderate-to-critical disease.
COVID-19 data are conflicting; not routine standard of care. Present as mixed evidence, not established benefit. Grade B/C (research) · D (extrapolation).
Mixed COVID picture
Conflicting analyses
Analysis
Finding
Liu 2020 (observational)
Lower mortality signal in severe lymphocytopenia cohort
Shang 2022/23 meta-analysis
No significant mortality effect
Soeroto 2023 meta-analysis
Possible benefit (moderate–critical)
Vaccine-response / immune-adjuvant (research)
No established public dose
Grade D/P
Dose
Not standardized; trials are variable/ongoing. No established public dose algorithm for broad vaccine enhancement.
FDA materials noted insufficient evidence to conclude Tα1 is effective as a vaccine enhancer. Avoid "boosted vaccine response" claims outside specific studied populations. Grade D/P.
Adjuvant status
Why this stays research-only
Issue
Detail
No standard dose
Trial-specific only
Endpoints unvalidated
Titers ≠ clinical protection here
Population-specific
Studied mainly in immunocompromised
In-vitro / ex-vivo research exposure
Mechanistic studies only
Grade P
Concentration
Cell-culture concentration varies by study; experimental concentration-response only.
Readouts
DC maturation markers, cytokines, T-cell activation, PD-1/PD-L1, IDO.
Not translatable directly to human dosing. Grade P.
Lab readouts
What in-vitro studies measure
Readout
Reflects
DC maturation markers
Antigen-presentation priming
Cytokines (IL-12, IFN)
Th1 signaling
IDO activity
Tolerance arm
L2 · Reconstitution math (research only)
Reconstitution & Dose Calculator
This calculator validates concentration and draw-volume arithmetic only (working unit: mg). It is not a prescribing tool. Tα1 is not FDA-approved in the U.S. and is flagged for compounding safety; hepatitis, sepsis, and infection care belong with a clinician and standard-of-care therapy. Vial sizes are configuration examples.
Concentration
—
Draw volume
—
Units (U-100)
—
Doses/vial
—
Basis
—
04 · Combinations
Combinations — clinical adjuncts, not wellness stacks.
Tα1's documented combinations come from clinical trials, not the supplement world: it was paired with interferon and peginterferon/ribavirin in hepatitis, layered onto standard care in sepsis and COVID, and discussed as an oncology adjunct. The recurring theme is that the background therapy is the established treatment and Tα1 is the immune-modulating add-on whose benefit varies by setting. The most important caution is in immune-conflicted patients — transplant, active autoimmunity, immunotherapy — where modulating immunity may work against the goal.
Tα1 + Interferon-alpha
HCV/HBV adjunct (historical)
Tα1IFN-α
An immune-adjuvant strategy in chronic HCV/HBV; trials combined Tα1 with interferon regimens. A randomized HCV trial tested Tα1 plus interferon. IFN carries a significant adverse-effect burden and is no longer first-line HCV care, so this is historical context, not current practice. Grade B.
Component
Role
IFN-α
Antiviral backbone (dated)
Tα1
Immune adjunct
Tα1 + Peginterferon / Ribavirin
HCV retreatment
Tα1PEG-IFNRibavirin
A nonresponder-retreatment strategy: a large trial (n=552) tested adding Tα1 to peginterferon/ribavirin for HCV nonresponders. HCV care has since been transformed by direct-acting antivirals, so this combination is largely of historical interest. Grade B.
Component
Note
PEG-IFN/RBV
Superseded by DAAs
Tα1
Adjunct in retreatment
Tα1 + Standard Sepsis Care
Mixed / negative
Tα1ICU standard care
Intended to reverse sepsis-associated immune suppression as an add-on to ICU care. The large 2025 TESTS RCT found no clear mortality benefit, tempering earlier positive meta-analyses. An active research question, not an established adjunct. Grade A/B (mixed).
Element
Status
Standard ICU care
Foundation
Tα1 add-on
No clear benefit (2025)
Tα1 + Standard COVID-19 Care
Conflicting
Tα1Standard COVID care
An immune-restoration strategy in hospitalized COVID-19. Evidence conflicts — some analyses found no mortality effect, others suggested possible benefit in more severe disease. Not routine standard of care. Grade B/C (mixed).
Element
Status
Standard COVID care
Foundation
Tα1 add-on
Conflicting data
Tα1 + Oncology Therapy
Specialist-only
Tα1Chemo / immunotherapy
An immune-surveillance / chemotherapy-adjunct rationale discussed in reviews. Reviews describe oncology-adjunct use, but immune effects may conflict with checkpoint inhibitors, transplant status, or immune toxicities. Specialist oversight is mandatory. Grade C/D.
Setting
Concern
Checkpoint inhibitors
Possible interaction
Chemo adjunct
Specialist-directed only
Hard-constraint clinical note — Avoid unsupervised Tα1 use in solid-organ transplant recipients, active autoimmune flares, active malignancy under immunotherapy, or patients on immunosuppressive regimens — modulating immunity can directly conflict with treatment goals. Every documented combination above comes from a clinical trial under supervision, layered on established standard-of-care therapy. None of this is a basis for self-directed "immune stacking."
05 · Safety & contraindications
Generally well-tolerated — with real immune and quality cautions.
Across hepatitis trials Tα1 has been notably well-tolerated, with injection-site reactions the most common adverse event. The meaningful cautions are mechanistic and practical rather than acute-toxicity: modulating immunity is risky in transplant, active autoimmunity, and immunotherapy settings; and in the U.S. the FDA has flagged compounded Tα1 for immunogenicity (aggregation), peptide impurities, and inconsistent API characterization — quality risks that gray-market product compounds further.
Safety signals & risks
Generally favorable tolerabilityHBV RCTs and reviews report few significant adverse events. Grade B.
Injection-site irritationThe most commonly reported AE in human reviews. Grade D.
Autoimmune activation (theoretical)TLR/T-cell modulation may worsen activation in susceptible patients. Grade D.
Transplant rejection risk (theoretical)Immune stimulation may oppose immunosuppressive therapy. Grade D.
Cancer-immunology uncertaintyMay interact with immunotherapy or tumor immune-escape pathways. Grade D.
Compounded-product quality riskFDA flags immunogenicity (aggregation), peptide impurities, and API-characterization concerns. Grade D.
Cytokine imbalance (context-dependent)Effects on IL-12/IFN/IL-2/T-cell signaling vary by setting. Grade P/D.
Unregulated-source contaminationResearch-chemical peptides may be mislabeled, impure, or misdosed. Grade D.
Practical safety framework
Acute tolerability is reassuring; the cautions are contextual
The trial safety record is favorable and dominated by local injection reactions. The real risk is mechanistic: in transplant, active autoimmunity, or immunotherapy, recalibrating immunity may work against the clinical goal — which is why those settings are contraindications, not dosing adjustments.
Quality is a US-specific problem
FDA's compounding review flags immunogenicity (potentially amplified by aggregation), peptide-related impurities, and weak API characterization. A regulated thymalfasin ampoule abroad and a gray-market "research" vial are not the same product.
Don't let it delay real care
For hepatitis, sepsis, or serious infection, the established standard of care is the treatment. Tα1 is at most an adjunct in specific studied settings — never a substitute for antivirals or hospital management.
Contraindications & cautions
Condition / scenario
Concern
Severity
Solid-organ transplant
Possible immune activation against graft
High
Active malignancy on immunotherapy
Interaction with checkpoint strategy
High
Pregnancy / lactation
Insufficient safety data
High
Pediatric non-trial use
Insufficient safety data
High
Severe allergy to peptide/excipients
Hypersensitivity risk
High
Uncontrolled infection (outpatient)
Self-treatment may delay proper care
High
Chronic HBV/HCV without antiviral care
May delay standard therapy
High
Use from unregulated source
Impurity, sterility, mislabeling
High
Active autoimmune disease flare
Immune modulation may worsen symptoms
Moderate–High
Competitive athlete
Anti-doping uncertainty — verify Global DRO
Moderate–High
Fever / rash / systemic reaction
Stop and evaluate
Hold
Injection-site reaction
Rotate site; monitor
Monitor
06 · Evidence base
A real clinical record — read by indication.
This is the strongest human evidence base of any peptide in the atlas's immune cluster: multiple randomized trials and meta-analyses spanning chronic hepatitis B/C, sepsis, and COVID-19, plus mechanistic work in Blood and other journals. The honest reading is by indication. Hepatitis B/C: historically meaningful, now partly superseded by modern antivirals. Sepsis: a large 2025 phase 3 RCT (TESTS) found no clear mortality benefit, reshaping a previously positive picture. COVID-19: conflicting. Wellness, longevity, and broad "immune optimization" claims remain Grade D/P unless tied to a specific study.
HBV · RCTs
Grade B
Multiple RCTs of 1.6 mg SC twice weekly × 6 months in chronic hepatitis B. Mutchnick, You, Chien.
Sepsis · 2025
Negative
TESTS phase 3 (n=1106): 28-day mortality 23.4% vs 24.1%, HR 0.99. No clear benefit.
COVID · meta
Conflicting
9-study meta-analysis (5352 pts) found no significant mortality effect; others suggest possible benefit. Mixed.
Mechanism
Established
TLR9/MyD88/IRF7, DC priming, IDO tolerance in Blood and other journals. Grade P.
APhase 3 RCT · sepsis
TESTS (2025) — thymosin α1 for sepsis
The landmark recent trial: a multicentre, double-blind, placebo-controlled phase 3 RCT (n=1106; 1.6 mg SC q12h up to 7 days) found 28-day all-cause mortality of 23.4% (Tα1) vs 24.1% (placebo), HR 0.99 (95% CI 0.77–1.27), with no clear benefit. Prespecified subgroup signals by age and diabetes are exploratory and hypothesis-generating only.
A systematic review/meta-analysis of 9 studies (5352 patients) found no statistically significant mortality effect of Tα1 in adult COVID-19 — the higher-quality anchor on the "no clear benefit" side of a genuinely conflicting evidence base.
A randomized controlled trial (n=97) of 1.6 mg SC twice weekly for ~6 months studied Tα1's effect on chronic hepatitis B response versus placebo — one of the foundational HBV trials underpinning the classic dosing regimen, alongside You et al. which also demonstrated a treatment effect in chronic HBV.
Ciancio et al. (2012) — Tα1 + PEG-IFN/ribavirin retreatment
A large RCT (n=552) testing the addition of Tα1 to peginterferon/ribavirin for chronic HCV nonresponders — the biggest adjunct-therapy trial, though the result and the whole approach have been overtaken by direct-acting antivirals.
Sherman et al. (1998) — Tα1 + interferon in chronic HCV
A randomized trial (n=109) of Tα1 1.6 mg SC twice weekly combined with interferon for chronic hepatitis C — an early test of the immune-adjuvant strategy in HCV, from the pre-DAA era, preceded by Andreone et al.'s small double-blind HCV pilot (n=19).
A pre-TESTS systematic review/meta-analysis of RCTs suggested Tα1 might reduce sepsis mortality, but with study-quality concerns — the positive prior that the large negative 2025 TESTS trial subsequently challenged. earlier sepsis meta-analysis.
Soeroto et al. (2023) — Tα1 in moderate–critical COVID-19
A systematic review/meta-analysis suggesting Tα1 may reduce mortality specifically in moderate-to-critical COVID-19 — the counterpoint analysis showing why the COVID evidence is best described as conflicting rather than settled either way.
An observational cohort reporting a lower-mortality signal with Tα1 in severe COVID-19 patients with marked lymphocytopenia, framed around restoring lymphocyte counts and reversing T-cell exhaustion — hypothesis-generating, with observational-design limits.
Romani / Bozza et al. — Tα1 TLR9/MyD88/IRF7 antiviral sensing
Mechanistic work showing Tα1 activates TLR9/MyD88/IRF7-dependent sensing to induce antiviral responses and prime dendritic cells for Th1 resistance — the molecular foundation for its antiviral immunomodulatory effects.
Demonstrated that Tα1 activates dendritic-cell tryptophan catabolism via IDO and establishes a regulatory environment — the tolerance arm that makes Tα1 a bidirectional immunomodulator rather than a pure immune stimulant.
FDA's compounding review places Tα1 in Category 2, citing immunogenicity risk for the 28-aa SC peptide (potentially amplified by aggregation), peptide-related impurities, and API-characterization concerns; it also notes weak/dated efficacy evidence (PEG-IFN superseded IFN-α; multiple COVID analyses found no mortality association).
GRADE summary — Tα1 has a much stronger human evidence base than most "research peptides," but its clinical relevance is indication-specific. HBV/HCV data (Grade B) are historically meaningful yet partly superseded by modern antivirals. Sepsis evidence (Grade A) was reshaped by the large 2025 TESTS RCT showing no clear mortality benefit. COVID-19 data (Grade A/B) remain conflicting. Mechanism (Grade P/C) is well-characterized. Wellness, longevity, and broad "immune optimization" claims should be graded D/P unless tied to a specific clinical study. Positioning: "a genuine immunomodulatory drug abroad with real but indication-specific and partly dated evidence — investigational and quality-flagged in the U.S., and not a general immune booster."
07 · Compare & contrast
Tα1 among the immune peptides.
Tα1 is the immune-modulation anchor of this cluster — the one with real RCTs and foreign approvals. Its thymosin-family namesake TB-500 (thymosin beta-4) is a completely different molecule and mechanism (actin/repair, not immunity). KPV and LL-37 occupy adjacent immune/anti-inflammatory lanes with far thinner clinical evidence. The table keeps mechanism class and evidence tier honest — Tα1 stands out for having human RCTs, not for being approved in the U.S.
Peptide
Primary positioning
Mechanism class
Evidence tier
Route
Regulatory status
Thymosin alpha-1 / thymalfasin
Immune modulation; viral hepatitis; sepsis/COVID research
L1 · Consumer — Thymosin alpha-1 is a small immune-signaling peptide studied for helping the immune system coordinate T-cell, dendritic-cell, and antiviral responses. Its strongest human evidence is not for general wellness but for specific medical areas like chronic hepatitis. It's an approved medicine in many countries but not in the U.S., where the FDA has flagged safety concerns about compounded versions — so treat it as a medical therapy, not a wellness supplement.
L2 · Clinical — Thymalfasin is the synthetic form of thymosin alpha-1, a 28-aa N-acetylated thymic peptide with immunomodulatory activity. Studies most often use fixed-dose subcutaneous regimens — classically 1.6 mg twice weekly in chronic hepatitis — while inpatient sepsis/COVID studies use short-course daily/twice-daily regimens with mixed efficacy. Read the evidence by indication: hepatitis (partly dated), sepsis (2025 RCT negative), COVID (conflicting).
L3 · Research — Tα1 engages innate and adaptive immunity via dendritic-cell modulation, TLR2/TLR9 engagement, MyD88/IRF7/NF-κB signaling, Th1 cytokine support, T/NK-cell effects, and IDO-linked tolerance — a bidirectional immune-balancing model. Clinical outcomes remain highly context-dependent and should not be generalized into anti-aging or broad immune-optimization claims; the open questions are which indications and patient subgroups (e.g. the exploratory TESTS age/diabetes signals) actually benefit.
08 · References & evidence
Source register.
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. For Tα1 the firmest sources are the phase 3 TESTS RCT and the COVID meta-analysis (Grade A), the hepatitis B/C RCTs (Grade B), the mechanistic Blood papers (Grade P), and the FDA/database/regulatory records (Grade D). This is the highest-clinical-evidence immune peptide in the atlas — which is exactly why its US-investigational, quality-flagged status and its indication-specific (and partly negative) results deserve equal prominence.